Sign In
Buy FUSN
$13.26
+0 (+0%)
At Close: Sep 04, 2020
5 Stocks to Bet on in an Innovation-Driven Drug Industry
12:02pm, Thursday, 20'th Oct 2022
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US
03:58pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock
What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock
04:00pm, Thursday, 13'th Oct 2022 Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near
What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock
01:33pm, Thursday, 13'th Oct 2022
Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022
02:04pm, Friday, 16'th Sep 2022 Benzinga
Upgrades
Morgan Stanley upgraded the previous rating for Alcoa Corp (NYSE:AA) from Equal-Weight to Overweight. Alcoa earned $2.67 in the second quarter, compared to $1.49 in the year-ago quarter. The
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
09:21am, Thursday, 15'th Sep 2022 Benzinga
Gainers
AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.
Avenue Therapeutics,
Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why
06:10pm, Wednesday, 14'th Sep 2022 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
02:42pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
02:07pm, Wednesday, 07'th Sep 2022 Benzinga
Upgrades
Macquarie upgraded the previous rating for Netflix Inc (NASDAQ:NFLX) from Underperform to Neutral. Netflix earned $3.20 in the second quarter, compared to $2.97 in the year-ago quarter. At th
After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN)
01:35pm, Friday, 12'th Aug 2022 Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street an
$1.7 Million Bet On Offerpad Solutions? Check Out These 3 Penny Stocks Insiders Are Buying
12:36pm, Friday, 12'th Aug 2022 Benzinga
U.S. producer prices dropped 0.5% month-over-month in July, following a revised 1% increase in the previous month. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase
After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN)
11:17am, Friday, 12'th Aug 2022
Fusion Pharmaceuticals Inc. (FUSN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street an
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates
12:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the sto
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the sto
Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?
02:00pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
